We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+42.22%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$438M
AUM Growth
+$53.9M
(+14%)
Cap. Flow
+$17.1M
Cap. Flow
% of AUM
3.9%
Top 10 Holdings %
Top 10 Hldgs %
64.1%
Holding
37
New
6
Increased
12
Reduced
11
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$17M |
| 2 |
Phreesia
PHR
|
+$12.7M |
| 3 |
HOLX
Hologic
HOLX
|
+$9.71M |
| 4 |
Viatris
VTRS
|
+$8.37M |
| 5 |
Quest Diagnostics
DGX
|
+$7.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$11.2M |
| 2 |
CMD
Cantel Medical Corporation
CMD
|
+$10.1M |
| 3 |
HMSY
HMS Holdings Corp.
HMSY
|
+$7.75M |
| 4 |
Pacira BioSciences
PCRX
|
+$6.48M |
| 5 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$6.05M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.28% |
| 2 | Industrials | 4.25% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$781B
| $512K | 0.12% |
8,000
+3,000
| +60% | +$924K |
|
27
CALL
Charles River Laboratories
CRL
$10.8B
| $279K | 0.06% |
+218
| New | +$30.2K |
|
|
28
CALL
Johnson & Johnson
JNJ
$641B
| $125K | 0.03% |
+250
| New | +$33.9K |
|
29
CALL
Haemonetics
HAE
$3.63B
| $24K | 0.01% |
+500
| New | +$60.5K |
|
30
PUT
Abbott
ABT
$182B
| – | – |
-900
| Closed | -$233K |
|
31
PUT
Medpace
MEDP
$16.5B
| – | – |
-350
| Closed | -$116K |
|
32
CALL
iShares S&P 100 ETF
OEF
$19.8B
| – | – |
-10,000
| Closed | -$110K |
|
33
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.2B
| – | – |
-5,000
| Closed | -$540K |
|
|
MDRX
34
CALL
DELISTED
Veradigm Inc. Common Stock
MDRX
| – | – |
-2,000
| Closed | -$208K |
|
|
CMD
35
DELISTED
Cantel Medical Corporation
CMD
| – | – |
-135,000
| Closed | -$10.1M |
|
|
GWPH
36
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| – | – |
-25,000
| Closed | -$2.88M |
|
|
HMSY
37
DELISTED
HMS Holdings Corp.
HMSY
| – | – |
-225,000
| Closed | -$7.75M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, Tamarack Advisers held 37 positions worth $438M, up 14% from $384M the previous quarter. Its ten largest holdings account for 64% of the portfolio.
Tamarack Advisers deployed $17.1M of net new capital in Q4 2019, opening 6 new positions and adding to 12 existing holdings. Its largest new stake was Johnson & Johnson: 125,000 shares worth $18M.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 86% a quarter earlier, followed by Industrials.
On the sell side, the largest reduction was Portola Pharmaceuticals, Inc., an estimated $11.2M trimmed.
- Tamarack Advisers's largest Q4 2019 buy was Johnson & Johnson: 125,000 shares worth $18M.
- Tamarack Advisers added most to Phreesia in Q4 2019, an estimated $12.7M increase.
- Tamarack Advisers's biggest Q4 2019 reduction was Portola Pharmaceuticals, Inc., cutting an estimated $11.2M.
- Tamarack Advisers fully exited Cantel Medical Corporation in Q4 2019, selling an estimated $10.1M.
- Tamarack Advisers's ten largest holdings make up 64% of its $438M portfolio in Q4 2019.
- Tamarack Advisers opened 6 new positions and closed 8 in Q4 2019.
- Tamarack Advisers's portfolio value rose 14% quarter-over-quarter to $438M.
Based on Tamarack Advisers's 13F filing for Q4 2019, filed 11 Feb 2020.